Abstract: Provided are a pharmaceutical composition and a method for treating a microbial infection in a subject in need thereof. In some cases, the composition comprises at least about 10% of thujopsene and at least about 10% of totarol. The present disclosure also provides a pharmaceutical composition and a method for treating a viral infection in a subject in need thereof. In some cases, the method comprises administering to the subject in need thereof a therapeutically effective amount of a composition comprising at least about 10% of thujopsene.

Abstract: An optical system for hologram displays is disclosed. According to an embodiment of a present disclosure, the optical system comprising a polarizing beam splitter for reflecting a light wave when the light wave is horizontally polarized or transmitting a light wave when the light wave is vertically polarized, a second quarter wave plate, a half mirror, and a first quarter wave plate, sequentially arranged in a first direction from the polarizing beam splitter, a third quarter wave plate and a first mirror, sequentially arranged in a second direction from the polarizing beam splitter, a fourth quarter wave plate and a second mirror, sequentially arranged in a third direction from the polarizing beam splitter, which is a direction opposite to the second direction and a reflective polarizer arranged in a fourth direction from the polarizing beam splitter.

Abstract: The present invention relates to a primer and probe set composition for CNV detection of a c-Met gene, and a kit comprising the same. By using the primer and probe set composition for CNV detection according to the present invention, it is possible to predict a prognosis of a c-Met-expressing cancer patient or a risk of mutation occurrence and to provide information required for targeted therapy of cancer, so as to be effectively used to provide clues for future treatment directions, as well as to determine a need to administer an anticancer drug, and to monitor the metastasis or recurrence of cancer.

Abstract: Pharmaceutical compositions and methods of using maleate salts of triazolopyrazine derivatives are provided. In some aspects, the pharmaceutical compositions have improved storage stability and pharmacokinetic properties. The maleate salts of triazolopyrazine derivatives bind competitively to the phosphorylation site of c-MET kinase and can be used for the treatment or prevention of various hyper proliferative disorders.

Abstract: Disclosed is a display device including a display panel including a pixel, a scan driver, and a driving controller that controls driving of the scan driver. The scan driver provides the pixel with a first mode scan signal having a first active period and a second active period in a first mode and provides the pixel with a second mode scan signal having a compensation active period in a second mode. The driving controller determines whether an operating frequency of the display device corresponds to one of predetermined compensation frequencies in a variable frequency mode, and operates the scan driver in the first mode or the second mode depending on a determination result of the determining.

Abstract: A display device includes a display panel, a gate driver, and a driving controller. The display panel includes a pixel. The gate driver applies an anode initialization signal to the pixel. The driving controller receives a horizontal synchronization signal, receives input image data at a variable frame frequency, and controls the gate driver. A frame period for the display panel includes a scan period and one or more hold periods, the driving controller generates a count value by counting a number of pulses of the horizontal synchronization signal, and determines a current frame period as the hold period when the count value exceeds a reference value, and a time length of the anode initialization signal in each of the one or more hold periods is longer than a time length of the anode initialization signal in the scan period.

Abstract: Provided are a composition and a method for preventing, treating, or ameliorating a skin disease or condition. In some cases, the method comprises administering to the subject in need thereof a therapeutically effective amount of a composition comprising at least about 10 v/v % of thujopsene. In some cases, the skin disease or condition comprises a skin inflammatory disease, an allergic disease, a skin wound, a skin aging-related condition, or particulate matter (PM2.5)-associated condition.

Abstract: Disclosed is an image generating device, which includes a measurement device including a plurality of transmitters and a plurality of receivers for a multistatic measurement of an object, an image preprocessing device that receives a raw image signal corresponding to the multistatic measurement from the measurement device and generates a preprocessed image signal based on the raw image signal, an image amplifier that generates an amplified image signal based on the preprocessed image signal, and an image restorer that generates a restored image signal corresponding to the object based on the amplified image signal, and the image amplifier is further configured to set up a first virtual transmitter and a first virtual receiver, to obtain first measurement data of a first target transmitter closest to the first virtual transmitter among the plurality of transmitters and a first target receiver closest to the first virtual receiver among the plurality of receivers.

Abstract: A camsylate salt of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

Abstract: Disclosed are a salt (camsylate salt) of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

Abstract: Provided are a pharmaceutical composition and a method for treating a microbial infection in a subject in need thereof. In some cases, the composition comprises at least about 10 % of thujopsene and at least about 10% of totarol. The present disclosure also provides a pharmaceutical composition and a method for treating a viral infection in a subject in need thereof. In some cases, the method comprises administering to the subject in need thereof a therapeutically effective amount of a composition comprising at least about 10% of thujopsene.

Abstract: Disclosed are a salt (camsylate salt) of D(+)-10-camphorsulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

Abstract: Disclosed are a salt (mesylate salt) of methanesulfonic acid and a triazolopyrazine derivative of formula (1), pharmaceutical compositions thereof, methods of making the salt, and therapeutic use thereof:

Abstract: Disclosed is an image data generating method. Operations of emitting electromagnetic waves to an object and receiving scan signals scanning the object are performed by using a multi-static transceiver. First image data of a low resolution are generated based on the scan signals. when a first condition associated with the first image data is satisfied, second image data of a high resolution associated with a sub-region of the first image data are generated. When a second condition associated with the second image is satisfied, third image data based on the first image data and the second image data are generated.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: In embodiments of the present disclosure, disclosure is an immunogenicity prediction method comprising the steps of: acquiring information about synthetic long peptides for treating carcinoma in a subject through an immunogenicity prediction device; processing the synthetic long peptides by one processing method of embedding, one-hot encoding, and BLOSUM through the immunogenicity prediction device, and outputting one or more antigen feature values based on the processed data; inputting the cleavage probability vector for each position of the synthetic long peptides through the immunogenicity prediction device to output one or more cleavage feature values; inputting a neoantigen peptide sequence, an HLA class I sequence, an HLA class II sequence within the synthetic long peptides through the immunogenicity prediction device to output one or more neoantigen feature values related to the immunity and binding affinity to the neoantigen peptide sequence; and outputting an immunogenicity score of the neoantigen pe

Abstract: A 3D optical microscope device of a small form factor optical system is disclosed. A transmission optical system device comprises a first lens having a left side disposed in contact with an input plane, and a second lens having a right side disposed in contact with a rear focal plane and disposed at a position spaced apart by a focal length of the first lens. The first lens and the second lens Fourier-transform a light signal incident on the input plane and output the transformed signal to the rear focal plane.

Abstract: A holographic optical system and a holographic display method may be efficiently applied when using a spatial light modulator (SLM). A holographic display apparatus includes a spatial light modulator (SLM) configured to reproduce a hologram, and an optical system configured to perform Fourier transform with respect to the hologram of the SLM using a pair of first and second lenses, the first and second lenses being confocal. A Fourier plane which is a display reference image plane is positioned in the same plane space as the second lens.

Abstract: Proposed are an organic-inorganic composite synthetic resin using a highly flame-retardant organically modified nanoparticle, and a production method thereof. The method for producing the organic-inorganic composite synthetic resin using a highly flame-retardant organically modified nanoparticle a includes the steps of: adding and stirring metal ion-based phosphinate, melamine cyanurate, and nanoclay to a container containing an aqueous or oily solvent, applying ultrasonic waves and high pressure energy to the stirred solution to prepare a highly flame-retardant organically modified silicate solution through a chemical bonding, and then adding a synthetic resin to form synthetic leather and foam used as life consumer goods to the silicate solution, processing and drying it.

Abstract: Proposed are an organic-inorganic composite synthetic resin using a highly flame-retardant organically modified nanoparticle, and a production method thereof. The method for producing the organic-inorganic composite synthetic resin using a highly flame-retardant organically modified nanoparticle includes the steps of: adding and stirring metal ion-based phosphinate, melamine cyanurate, and nanoclay to a container containing an aqueous or oily solvent, applying ultrasonic waves and high pressure energy to the stirred solution to prepare a highly flame-retardant organically modified silicate solution through a chemical bonding, and then adding a synthetic resin to form synthetic leather and foam used as life consumer goods to the silicate solution, processing and drying it.